Pricing

Syros Pharmaceuticals Inc (SYRS)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Nancy A. Simonian
Employees:
120
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140
617-744-1340
Stock Split History
DateRatio
2022-09-19 1:10
Syros Pharmaceuticals, Inc. focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available